The changing face of nicotine use in England: Age‐specific annual trends, 2014 to 2024
Addiction · 2026
DOI: 10.1111/add.70243 ↗At a glance
Journal article in Addiction, 2026. Written by Sarah E Jackson and 6 co-authors. Institution: Department of Behavioural Science and Health, University College London, London, UK. Major MEDLINE topics: Vaping, Smoking. Cited 10 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cancer Research UK.
Abstract (original language)
Aims
To examine age‐specific trends in patterns of nicotine use in England between 2014 and 2024, including types of products used, exclusive and dual use of smoking and vaping, smoking frequency and the smoking history of those who vape.
Design
Repeat monthly cross‐sectional analysis of data from a nationally representative survey (the Smoking Toolkit Study).
Setting
England, 2014–2024.
Participants
217 433 adults (≥18y).
Measurements
Prevalence of (non‐medicinal) nicotine use overall and by product type (combustible tobacco, e‐cigarettes, heated tobacco products and nicotine pouches), exclusive and dual use of smoking and vaping, daily versus non‐daily smoking and smoking history among those who vape. Estimates were stratified by age group (18–24, 25–34, 35–44, 45–54, 55–64, ≥65y) and year. Prevalence ratios (PR) with 95% confidence intervals (CI) were calculated to quantify relative changes in prevalence from 2014 to 2024.
Findings
Nicotine use patterns varied markedly by age. Among 18–24‐year‐olds, vaping prevalence increased fivefold, from 5.0% in 2014 to 25.0% in 2024 (PR = 5.00; 95% CI = 4.18–5.91), surpassing smoking by 2023. This contributed to an overall increase in nicotine use (26.1% to 36.5%; PR = 1.40; 95% CI = 1.29–1.53), despite declining smoking rates (25.3% to 19.9%; PR = 0.79; 95% CI = 0.71–0.88). In this age group, exclusive vaping became the most common mode of nicotine use, while nicotine pouch use also increased. Daily smoking declined substantially among 18–24‐year‐olds who smoked, with a shift toward non‐daily smoking. Similar trends were observed among adults aged 25–44, though changes were smaller with increasing age. In older age groups (≥45), daily smoking declined modestly while vaping rose gradually, but there was little overall change in the prevalence of nicotine use. Most adults who vaped had a history of smoking, but the proportion who had never regularly smoked increased, particularly among 18–24‐year‐olds (4.3% to 34.3%; PR = 7.98; 95% CI = 4.56–26.2).
Conclusions
Generational shifts in nicotine use are occurring in England. Nicotine use has risen among young adults over the past decade, but they are increasingly moving away from daily cigarette smoking towards vaping or non‐daily smoking. While older adults have also shown movement away from daily smoking, traditional smoking patterns remain more prevalent in this group. These trends suggest vaping may gradually replace smoking as the dominant form of nicotine consumption.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Behavioural Science and Health, University College London, London, UK.
- Behavioural Research UK, London, UK.
ORCID profiles: Sarah E Jackson, Lion Shahab, Sharon Cox, Jamie Brown
Funding
- Cancer Research UK
Cite
APA
Jackson, S. E., Shahab, L., Buss, V., Tattan-Birch, H., Cox, S., Taylor, E., & Brown, J. (2026). The changing face of nicotine use in England: Age‐specific annual trends, 2014 to 2024. Addiction. https://doi.org/10.1111/add.70243
Vancouver
Jackson SE, Shahab L, Buss V, Tattan-Birch H, Cox S, Taylor E, et al. The changing face of nicotine use in England: Age‐specific annual trends, 2014 to 2024. Addiction. 2026. doi:10.1111/add.70243
BibTeX
@article{Jackson2026,
author = {Jackson, Sarah E and Shahab, Lion and Buss, Vera and Tattan-Birch, Harry and Cox, Sharon and Taylor, Eve and Brown, Jamie},
title = {The changing face of nicotine use in England: Age‐specific annual trends, 2014 to 2024},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70243}
}
EUVIMED